Triamcinolone Acetonide Shows No Direct Toxicity to Human Knee Cartilage

Reassessing the structural safety of intra-articular corticosteroids

Intra-articular corticosteroid injections remain a cornerstone of symptomatic management for knee osteoarthritis, particularly when inflammatory synovitis or acute pain flares limit patient mobility [1]. While these agents provide rapid analgesic effects, their long-term impact on joint health remains a subject of intense clinical debate [2]. Many practitioners balance the immediate benefits of pain reduction against reports suggesting that repeated steroid exposure may accelerate the progression of cartilage loss [3]. Current professional guidelines reflect this uncertainty, offering inconsistent recommendations that vary significantly across different medical societies [1]. Recent comparative trials have sought to weigh the efficacy of corticosteroids against biological alternatives or different delivery methods to minimize potential structural harm [4, 5]. A new study using human cartilage models now offers a detailed metabolic analysis to clarify whether these medications are directly responsible for joint degradation.

Simulating clinical exposure in human tissue models

To investigate the metabolic impact of triamcinolone acetonide on joint health, researchers utilized human cartilage harvested from two distinct sources to ensure clinical relevance across different patient populations. The first group consisted of healthy tissue obtained from cadaver donor knees with a mean age of 38 years (4 male donors), while the second group represented diseased tissue using remnants from total knee replacement surgeries with a mean age of 66 years (9 female, 7 male). By comparing these cohorts, the study aimed to determine how the corticosteroid affects both pristine and degenerated cartilage environments. The researchers focused on evaluating chondrocyte viability (the percentage of living cells within the cartilage matrix) alongside changes in gene expression that regulate tissue maintenance. The experimental design utilized two specific concentrations of triamcinolone acetonide: a high dose of 200 μM (0.087 mg/mL) and a low dose of 1 nM. To track the metabolic consequences of these exposures, the team employed a high-resolution click chemistry assay (a technique using specific, highly efficient chemical reactions to label and track newly synthesized molecules in biological systems). This method allowed for the precise quantification of glycosaminoglycan (GAG) and collagen synthesis while simultaneously monitoring GAG loss, providing a detailed view of matrix turnover. The study found that triamcinolone acetonide did not reduce chondrocyte viability and did not increase baseline glycosaminoglycan loss from the cartilage samples, suggesting a lack of direct cellular toxicity. To mirror various clinical scenarios, the researchers tested two distinct dosing regimens. The first was a continuous 14-day exposure designed to serve as a multiple-injection simulation, representing the prolonged presence of the drug within the joint space. The second regimen consisted of a 2-day exposure followed by a 14-day recovery period, which functioned as a single-injection simulation to observe the potential for tissue rebound or lasting suppression. While the continuous 14-day exposure to 200 μM triamcinolone acetonide reduced GAG synthesis by 26% in osteoarthritic cartilage (p < .001) and 18% in healthy cartilage (p = .004), the single-injection simulation produced no change in glycosaminoglycan or collagen synthesis in healthy cartilage, indicating that the metabolic effects of the steroid may be transient and dose-dependent.

Preservation of chondrocyte viability and matrix integrity

The primary concern regarding intra-articular corticosteroids is the potential for direct chondrotoxicity, yet the laboratory data suggest these fears may be overstated in the context of intact human tissue. In this analysis, the researchers found that triamcinolone acetonide did not reduce chondrocyte viability in the cartilage samples, maintaining the population of living cells necessary for ongoing tissue maintenance and repair. This lack of cellular death was consistent across both healthy and osteoarthritic specimens, even when exposed to concentrations as high as 200 μM, which far exceed typical clinical exposure levels. Furthermore, the study demonstrated that triamcinolone acetonide did not increase baseline glycosaminoglycan loss from the cartilage samples, indicating that the steroid does not trigger the immediate catabolic breakdown of the extracellular matrix that clinicians often associate with rapid joint degeneration. Beyond the preservation of existing matrix components, the findings provide a reassuring profile of the drug's safety at the cellular level. Under the specific experimental conditions of this study, triamcinolone acetonide had no measurable toxicity to chondrocytes in intact human cartilage, suggesting that the structural integrity of the joint remains stable during exposure. While the researchers observed a modest and reversible suppression of new matrix synthesis at high doses, the absence of direct toxicity or accelerated GAG depletion supports the use of triamcinolone for managing synovitis without the risk of immediate, steroid-induced cartilage degradation. For the practicing physician, these results indicate that the observed clinical benefits of triamcinolone acetonide in reducing inflammation do not come at the cost of direct chondrocyte destruction or acute matrix loss.

Downregulation of catabolic enzymes in osteoarthritic cartilage

The study investigated the molecular mechanisms by which triamcinolone acetonide influences the cartilage environment, specifically focusing on the expression of catabolic enzymes that drive tissue degradation. In healthy cartilage, the researchers found that triamcinolone acetonide downregulated MMP13 (matrix metalloproteinase 13, a primary enzyme responsible for breaking down the collagen framework) from a mean ± SD of 1.0 ± 0.8 to 0.4 ± 0.2 (P = .04). This suppressive effect was even more pronounced in diseased tissue, which is often characterized by an overabundance of these degradative proteins. In osteoarthritic cartilage, 200 μM triamcinolone acetonide downregulated MMP13 from 1.0 ± 0.7 to 0.2 ± 0.3 (P = .02), suggesting that the corticosteroid may actively mitigate the collagenolytic activity typically seen in the progression of joint disease. Beyond its impact on collagen breakdown, the treatment also targeted the degradation of aggrecan, a critical proteoglycan component of the cartilage extracellular matrix that provides compressive strength. In osteoarthritic cartilage, 200 μM triamcinolone acetonide downregulated ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5, an enzyme specifically involved in aggrecan degradation) from 1.0 ± 0.3 to 0.4 ± 0.1 (P = .03). By reducing the expression of these key degradative enzymes, triamcinolone acetonide may actually inhibit the biochemical pathways that lead to cartilage breakdown rather than accelerating them. For clinicians, these data provide a molecular basis for the drug's safety profile, indicating that intra-articular injections may help stabilize the cartilaginous matrix by suppressing the very enzymes responsible for its erosion during inflammatory flares.

Transient and reversible effects on matrix synthesis

While the study demonstrated a reduction in catabolic activity, the researchers also observed a corresponding downregulation of anabolic gene expression and matrix synthesis under specific conditions. In healthy cartilage, triamcinolone acetonide downregulated COL2A1 (type II collagen alpha 1 chain, the primary gene responsible for producing the structural collagen of cartilage) from 1.0 ± 0.3 to 0.5 ± 0.2 (P = .003). A similar effect was noted in diseased tissue, where 200 μM triamcinolone acetonide downregulated COL2A1 from 1.0 ± 0.3 to 0.7 ± 0.2 (P = .05) in osteoarthritic cartilage. These genetic changes translated to measurable reductions in the production of extracellular matrix components during prolonged exposure. Specifically, a continuous 14-day 200 μM triamcinolone acetonide exposure reduced glycosaminoglycan (GAG) synthesis by 26% in osteoarthritic cartilage (P < .001) and by 18% in healthy cartilage (P = .004). Notably, lower concentrations appeared more benign for GAG production, as exposure to 1 nM triamcinolone acetonide had no effect on glycosaminoglycan (GAG) synthesis. The impact on collagen production followed a similar pattern of dose dependency in healthy tissue. Collagen synthesis was reduced in healthy cartilage by 25% following exposure to 200 μM triamcinolone acetonide (P < .001) and by 21% following exposure to 1 nM triamcinolone acetonide (P = .004). However, the clinical relevance of these findings is clarified by the recovery data. The researchers found that a single-injection simulation (2-day exposure followed by 14-day recovery) produced no change in GAG or collagen synthesis in healthy cartilage. This indicates that triamcinolone acetonide only modestly and reversibly suppressed matrix synthesis at doses far exceeding clinical exposure. For the practicing clinician, these results suggest that while triamcinolone may temporarily slow the production of new cartilage matrix, this effect is transient and does not result in a permanent deficit in matrix synthesis when administered as a discrete clinical injection.

References

1. Primorac D, Molnar V, Matišić V, et al. Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines. Pharmaceuticals. 2021. doi:10.3390/ph14030205

2. Wang Q, Mol MF, Bos PK, et al. Effect of Intramuscular vs Intra-articular Glucocorticoid Injection on Pain Among Adults With Knee Osteoarthritis: The KIS Randomized Clinical Trial.. JAMA network open. 2022. doi:10.1001/jamanetworkopen.2022.4852

3. Mekariya K, Manop P, Chernchujit B. Efficacy of single intra-articular 2% sodium hyaluronate versus corticosteroid injection in isolated patellofemoral osteoarthritis: A double-blind, randomized controlled trial.. Journal of ISAKOS : joint disorders & orthopaedic sports medicine. 2026. doi:10.1016/j.jisako.2025.101038

4. Wattanasirisombat K, Boontanapibul K, Pinitchanon P, Pinsornsak P. Betamethasone and Triamcinolone Acetonide Have Comparable Efficacy as Single Intra-Articular Injections in Knee Osteoarthritis: A Double-Blinded, Randomized Controlled Trial.. The Journal of bone and joint surgery. American volume. 2026. doi:10.2106/JBJS.25.00100

5. Pandey S, Singh L, Singh AJ, Moirangthem M, Priyanka S. Comparison of Ultrasound-guided Intra-articular Injection of Platelet-rich Plasma and Triamcinolone Acetonide in the Reduction of Pain and Functional Improvement in Primary Temporomandibular Joint Osteoarthritis: A Randomised Controlled Trial. Indian Journal of Physical Medicine and Rehabilitation. 2025. doi:10.4103/ijpmr.ijpmr_71_24